News
AI innovation to be celebrated at Femtech World’s third-annual awards event
Health tech companies advancing female health outcomes through AI innovation are being encouraged to enter Femtech World’s third-annual awards event.
The awards celebrate the best examples of leadership, innovation and impact in key areas that affect women’s health and wellbeing.
Introduced in 2025, the AI Innovation award honours an individual or organisation pioneering the use of artificial intelligence to transform women’s health.
The winner will have demonstrated groundbreaking innovation in applying AI to improve diagnosis, treatment accessibility, or overall health outcomes for women.
The award is sponsored by Women’s Health Week, whose flagship women’s health conferences across Europe and the USA unite the complete ecosystem.
This includes visionary founders, strategic investors, multinational corporations, and specialised service providers – accelerating life-changing solutions that address women’s most critical unmet health needs.
Femi Adetoro, marketing manager, Women’s Health Week, said: “We’re happy to be back partnering with the Femtech World Awards for another year as a part of our commitment to highlighting the innovators disrupting women’s heath with investable and scalable products/services.”
Molly Taylor, head of content, Women’s Health Week, added: “We’re especially excited to be sponsoring the AI Innovation category this year as it aligns strongly with our mission to spotlight innovation that’s driving health impact for women worldwide.”
The AI Innovation award is one of 10 featuring at the event, which last year attracted entries from across the UK, Europe and North America.
Award winners will receive a trophy and the opportunity to be interviewed by Femtech World.
Both winners and shortlisted entries will receive extensive coverage across all Femtech World platforms.
Find out more and enter for free here.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Menopause3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Wellness4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






